This provides an opportunity for controlling the dynamics of binding and inhibition effectiveness; given the rise in pH-selective PD-1/PD-L1 pathway inhibitors, despite the challenges posed by tumor heterogeneity, where different regions within a tumor exhibit varying pH levels, targeting acidic environments remains effective [41]. Here, PDCD1 is linked to neoplasm.